Evaluation of EGFR and K-ras Mutations in Patients With Stage III NSCLC Treated on CALGB 30106
18 Years
N/A
Both
Lung Cancer
Trial Information
Evaluation of EGFR and K-ras Mutations in Patients With Stage III NSCLC Treated on CALGB 30106
OBJECTIVES:
- Determine the frequency of epidermal growth factor receptor (EGFR) and K-ras mutations
in patients with stage III non-small cell lung cancer (NSCLC) treated on CALGB 30106.
- Correlate presence or absence of EGFR and/or K-ras mutations with radiographic response
to treatment in these patients.
OUTLINE: Tissue samples are analyzed for epidermal growth factor receptor and K-ras
mutations.
PROJECTED ACCRUAL: A total of 49 patient specimens will be accrued for this study.
Inclusion Criteria
DISEASE CHARACTERISTICS:
- Diagnosis of stage III non-small cell lung cancer
- Treated on protocol CALGB-30106
PATIENT CHARACTERISTICS:
- Performance status 0-2
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Type of Study:
Interventional
Study Design:
N/A
Outcome Measure:
Frequency of epidermal growth factor receptor (EGFR) and K-ras mutations
Safety Issue:
No
Principal Investigator
Pasi Janne, MD, PhD
Investigator Role:
Study Chair
Investigator Affiliation:
Dana-Farber Cancer Institute
Authority:
United States: Federal Government
Study ID:
CDR0000491128
NCT ID:
NCT00898924
Start Date:
November 2005
Completion Date:
March 2006
Related Keywords:
- Lung Cancer
- stage IIIA non-small cell lung cancer
- stage IIIB non-small cell lung cancer
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
Name | Location |
|---|
